Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other Accumulated Expenses (2018)

Rein Therapeutics filings provide 1 years of Other Accumulated Expenses readings, the most recent being $3.6 million for Q4 2018.

  • For the quarter ending Q4 2018, Other Accumulated Expenses changed N/A year-over-year to $3.6 million, compared with a TTM value of $3.6 million through Dec 2018, changed N/A, and an annual FY2018 reading of $3.6 million, changed N/A over the prior year.
  • Other Accumulated Expenses hit $3.6 million in Q4 2018 for Rein Therapeutics.
  • The five-year high for Other Accumulated Expenses was $3.6 million in Q4 2018, with the low at $3.6 million in Q4 2018.